Facebook
Twitter
LinkedIn
Forward
Improving Biomarker Driven Precision Therapy in NSCLC: Less Common, More Complex: Multidisciplinary Discussion of Safety and Efficacy of TKIs for Rare Mutations in NSCLC September 29, 2021
Improving Biomarker Driven Precision Therapy in NSCLC: The Importance of an Integrated Multidisciplinary Approach Part 2 - Less Common, More Complex: Multidisciplinary Discussion of Safety and Efficacy of TKIs for Rare Mutations in NSCLC
Claiming Credit
Thank you for attending this webinar on September 29, 2021. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to claim your credit on the following page.
Biomarker based testing and precision medicine based approaches have become a standard to guide treatment decisions for metastatic non-small cell lung cancer (NSCLC) and are crucial even for early stage/resected patients. There are several barriers that prevent optimal testing for patients, but the discovery of novel molecular targets and subsequent development of targeted therapies make it critical to find ways to overcome these barriers. As treatment progresses, there is a potential to develop resistance mechanisms to commonly used targeted therapies; these new targets are identified by the integration of precision medicine.
There are more complex, rare mutations in NSCLC that warrant further discussion on their impact in clinical practice based on new data. It is imperative for all members of the lung cancer treatment team (oncologists, pathologists, pharmacists, nurse practitioners, nurses, and physicians’ assistants) to understand this data and recognize the complexity of managing these patients using a precision medicine based approach in both first line and subsequent line therapies.
At this webinar, learn clinical pearls needed to attain best outcomes for your patients with these mutations in a case-based conversation with expert faculty.
Overview of NSCLC and Transition Towards Biomarker Based Testing
Considerations Before Treatment Initiation with RET, MET, KRASG12C, and HER-2-Directed Therapy
Treatment Management Pearls During Therapy
Goals, Gaps in Practice, and Learning Objectives
The overall goal of this project is to help identify critical gaps in standard biomarker testing and help improve understanding of targeted based therapies for patients with non-small cell lung cancer (NSCLC). Furthermore, this educational series would allow oncology team members to become more familiar with the targeted based approaches for less common mutations and make treatment decisions to promote better care for patients.
This program is supported by an educational grant from Pfizer Inc.
Target Audience
The primary audience targeted with this educational series includes the lung cancer care team. This encompasses medical oncologists, pathologists, interventional radiologists, pharmacists, nurse practitioners, physicians’ assistants, and nurses involved with the care of patients with NSCLC.
Learning Objectives
At the end of this program, attendees should be able to:
- Identify operational and clinical barriers that may interfere with optimal biomarker based testing and develop initiatives to offset these barriers.
- Describe first and subsequent line targeted treatment approaches for adult patients with metastatic RET, KRASG12C, and MET, HER-2-mutated NSCLC
- Discuss strategies to mitigate adverse effects of treatment to improve long-term survival and quality of life for patients with RET, KRASG12C, and MET-mutated NSCLC
This session will take place virtually through Zoom on Wednesday September 29th from 5:00-6:00pm EST. :
At this webinar, learn clinical pearls needed to attain best outcomes for your patients with these mutations in a case-based conversation with expert faculty.
Overview of NSCLC and Transition Towards Biomarker Based Testing
Considerations Before Treatment Initiation with RET, MET, KRASG12C, and HER-2-Directed Therapy
Treatment Management Pearls During Therapy
Speakers
David Hughes, PharmD, BCOP
Clinical Pharmacy Manager Hematology/Oncology
Boston Medical Center
Dr. Hughes is a board-certified oncology pharmacist working in the outpatient hematology/oncology clinic at Boston Medical Center. He has championed successful quality improvement projects in the clinic, known for his dedication, hard work and ingenuity when dealing with patients and providers. His project on anti-emetic protocols for all highly emetogenic chemotherapy helped to transform clinic operations and improve patient experience. He has authored publications on pharmacy quality initiatives. He has research experience with COVID-19, pharmacokinetic software platforms for vancomycin, and recently a wealth of clinical trials in both oncologic and hematologic malignancies. Furthermore, he was co-awarded a RFP through Pfizer for the optimal management of oral chemotherapy in metastatic breast cancer with Dr. Naomi Ko. He has presented at local, regional, and national conferences and his expertise is sought out by many. Dr. Hughes will be the lead pharmacy specialist to help coordinate all patient access issues within specialty pharmacy realm to assure reduced time to initiation of therapy and successful clinical management.
Speaker has no relevant financial relationships to disclose.
Jasmine Patel, PharmD
Clinical Pharmacy Specialist – Hematology/Oncology
Boston Medical Center
Dr. Patel is a clinical pharmacy specialist in the outpatient hematology/oncology clinic at Boston Medical Center. In her first year at the institution, Jasmine co-led an initiative with our lead breast cancer oncologist (Dr. Naomi Ko, MD, MPH) to improve adherence and toxicity management of patients treated with oral chemotherapy for metastatic breast cancer. She was additionally awarded "Resident of the Year" for her dedication to her oncology patients and the pharmacy profession. Dr. Patel will support day-to-day pharmacy efforts by routinely calling and managing patients and assisting with PRO documentation within our EMR.
Speaker recieves grant funding from Pfizer Inc. for breast cancer research.
Umit Tapan, MD
Assistant Professor of Medicine, Department of Medicine, Boston University School of Medicine
Dr. Tapan is an Assistant Professor of Medicine at Boston University School of Medicine and a practicing Thoracic Oncologist at Boston Medical Center. He currently co-leads BMC thoracic oncology program and is the site-PI for clinical trials in thoracic malignancies. As a productive clinical researcher Dr. Tapan has authored numerous publications. His previous research efforts focusing on the role of c-cbl in pathophysiology of colorectal cancer have been published in prestigious journals. Dr. Tapan has been interested in racial disparity in cancer care since early years of his career and he has previously shown that African American patients with colorectal cancer have significantly lower survival despite equal access to care. His current research interests are racial disparities in lung cancer care, access to targeted treatments and immune checkpoint inhibitors in vulnerable populations. Most recently looking at disparities in chemotherapy receipt in extensive stage small cell lung cancer. (https://www.jtocrr.org/article/S2666-3643(20)30155-7/fulltext)
Speaker has no relevant financial relationships to disclose.
Planning Committee
Dana F. Price, MS, CHCP
Grants and Development Manager
Continuing Medical Education Office Boston University School of Medicine
David Hughes, PharmD, BCOP
Course Director
Clinical Pharmacy Manager Hematology/Oncology
Boston Medical Center
Jasmine Patel, PharmD
Clinical Pharmacy Specialist – Hematology/Oncology
Boston Medical Center
Umit Tapan, MD
CME Course Director
Assistant Professor of Medicine, Department of Medicine, Boston University School of Medicine
Elizabeth Tiani, AGACNP
NCPD Course Advisor
Instructor of Medicine, Medical Oncology
BUSM/BMC
Carmela A. Townsend, DNP, MS/MBA, RN
Accredited Provider Activity Director
Continuing Medical Education Office Boston University School of Medicine
Planners have nothing relevant to disclose.
CME Program Manager: Claire P. Grimble, CMP
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Contact Hours: 1.25 of which 1.25 is eligible for pharmacology credit.
CONTINUING EDUCATION CREDITS
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is an application-based educational activity. Pharmacists will receive 1.0 contact hours (0.10 CEUS) for the educational activity. No partial credit is available.
UNIVERSAL ACTIVITY NUMBERS (UAN) 0060-9999-21-029-L01-P
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 ANCC
- 1.00 Participation